KINN THERAPEUTICS AS
Operating
Kommersiell utvikling av medisinske og cellebiologiske hjelpemidler
basert på funksjonell genomikk og alt hva herved står i forbindelse,
herunder eierskap i andre selskaper og konsulenttjenester.
Tjenester innen bioteknologi.
Organization
- CEO
- MP
- Chairman of the board
- EM
Emmet Mccormack1977
- Years since formation
- 22 years
- since Sep 9, 2004
- Type
- Limited company
- VAT registered
- Yes
- Number of employees
- 6
Ownership
- Number of shares and share classes
- 350,691
- 1 share class
- Total number of shareholders
- 2
- persons
Financials
- Total operating income 2025
- 3,040,284
- NOK
- Annual total result 2025
- 383,835
- NOK
- Total equity 2025
- 2,636,391
- NOK
Last update: Feb 24, 2026
Locations
- Company addressLaboratoriebygget, 9 etg Haukeland University Hospital 5021 BERGEN, NorgeCopied!
- Postal addressc/o IFI, Univ of Bergen Laboratoriebygget, 8 etg. 5021 BERGEN, NorgeCopied!
Management
Management / administration
| Name | Role | Shares |
|---|---|---|
MP | Managing Director/CEO | - |
Board
| Name | Role | Shares |
|---|---|---|
BT | Board Member | 50 % directly |
JI 1959 | Board Member | - |
LB 1966 | Board Member | - |
EM 1977 | Chairman | 50 % directly |
Others
| Name | Role | Shares |
|---|---|---|
| Accountant | - |
Top 10 individual shareholders
| Name | Role | Shares |
|---|---|---|
EM 1977 | Chairman | 50 % directly |
BT | Board Member | 50 % directly |
Last update: Feb 14, 2026
Ownership
Company shareholders
| Name | Share class | Total number of shares | Share |
|---|---|---|---|
EM 1977 | Ordinary shares | 175,346 | 50 % |
BT | Ordinary shares | 175,345 | 50 % |
Last update: Jun 2, 2025
Financials
in NOK
Summary
| Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
Total operating income | 3,040,284 | 4,857,866 | 3,158,893 | 1,619,551 | 1,071,997 |
Annual Total Result | 383,835 | 1,705,496 | 147,662 | -742,574 | -1,642,018 |
Total assets | 3,013,258 | 2,620,571 | 1,348,740 | 697,169 | 1,507,410 |
Total liabilities | 376,866 | 368,015 | 801,680 | 297,770 | 365,436 |
Total equity | 2,636,391 | 2,252,557 | 547,060 | 399,399 | 1,141,973 |
P&L
| Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
Total operating income | 3,040,284 | 4,857,866 | 3,158,893 | 1,619,551 | 1,071,997 |
Total operating costs | 2,657,196 | 3,176,950 | 2,987,490 | 2,360,753 | 2,711,755 |
Operating result | 383,088 | 1,680,915 | 171,403 | -741,202 | -1,639,758 |
Financial income/costs | 747 | 24,581 | -23,742 | -1,372 | -2,260 |
Profit before tax | 383,835 | 1,705,496 | 147,662 | -742,574 | -1,642,018 |
Total tax & extraordinary income/cost | 0 | 0 | 0 | 0 | 0 |
Annual Total Result | 383,835 | 1,705,496 | 147,662 | -742,574 | -1,642,018 |
Balance overview
| Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
Total fixed assets | 103,724 | 0 | 0 | 9,685 | 73,843 |
Total current assets | 2,909,534 | 2,620,571 | 1,348,740 | 687,484 | 1,433,567 |
Total assets | 3,013,258 | 2,620,571 | 1,348,740 | 697,169 | 1,507,410 |
Short term debt | 376,866 | 368,015 | 801,680 | 297,770 | 365,436 |
Long term debt | 0 | 0 | 0 | 0 | 0 |
Total liabilities | 376,866 | 368,015 | 801,680 | 297,770 | 365,436 |
Contributed capital | 105,207 | 105,207 | 105,207 | 105,207 | 105,207 |
Retained earnings | 2,531,184 | 2,147,350 | 441,853 | 294,192 | 1,036,766 |
Total equity | 2,636,391 | 2,252,557 | 547,060 | 399,399 | 1,141,973 |
Total equity and liabilities | 3,013,258 | 2,620,572 | 1,348,740 | 697,169 | 1,507,410 |
Classification
21st company classification
BETA
Small company
Type of organization
Limited company
Classification of institutional sector
INNL
Domestic sectors
A_IKKE-FIN
Non-financial corporations
2100
Private non-financial incorporated enterprises